Compare Heron Therapeutics Inc (HRTX) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs SYSCO Corporation — how do they compare? Heron Therapeutics Inc trades at $0.41 (market cap $68.01M), while SYSCO Corporation trades at $78.14 (market cap $38.47B). The key difference: SYSCO Corporation is far larger — about 565.7× Heron Therapeutics Inc's market cap, and SYSCO Corporation pays a 2.81% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and SYSCO Corporation for 77 Days on average.
| HRTX | SYY | |
|---|---|---|
Market Cap | $68.01M | $38.47B |
Volume | 1,891,941 | 4,808,465 |
Sector | Health | Consumer Staples |
52-Week High | $1.49 | $91.16 |
52-Week Low | $0.27 | $69.30 |
Typical Hold Time | 35 Days | 77 Days |
Enterprise Value | $174.75M | $51.65B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3582, down 8.15% today, with a bullish technical signal from moving averages but mixed earnings. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates, continuing a trend of net losses. Analyst sentiment remains strongly positive with 89% buy ratings, though Zacks issued a Strong Sell rating in July 2026.
The outlook hinges on revenue stabilization and path to profitability. Investment opportunity lies in analyst optimism and product sales growth, but risks include persistent losses, high valuation multiples, and competitive pressures in the biotechnology sector.
Sysco (SYY) trades at $78.20, up 1.84% with neutral technical signals and strong institutional support. The stock shows solid fundamentals with $81.37B revenue, 2.08% net margin, and attractive valuation at P/E 21.37 and P/S 0.44. Recent corporate actions include a $0.55 dividend and $1B stock offering, while the company reaffirmed fiscal 2027 guidance and launched a $500M AI efficiency program.
Sysco presents a balanced investment case with 60% analyst buy ratings and $85.75 consensus target offering 9.6% upside. The food distribution leader benefits from consistent revenue growth and AI-driven efficiency initiatives, though margin pressure and competitive threats warrant monitoring. Current valuation appears reasonable given the company's market position and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
